
Kura Oncology, Inc.
93
Recent developments include Kura Oncology's Q3 2026 earnings call and report of a quarterly loss with revenue exceeding expectations, launch of a diabetes-focused venture backed by $50 million, and clinical development updates on diabetes candidate KO-7246.
- Kura Oncology held its Q3 2026 earnings call and reported a quarterly loss while surpassing revenue expectations [N1][N2].
- The company launched a $50 million-backed diabetes venture focused on an oral menin inhibitor, expanding beyond oncology [N7].
- Kura Oncology and Caspian Therapeutics outlined the development path for diabetes candidate KO-7246 [N8].
- Jennifer Fulk was named CFO in September 2026, indicating leadership changes [N1].
- Initial KOMZIFTI sales reached $2.1 million, and the company secured $195 million in milestone payments as of early 2026 [N1].
Kura Oncology, Inc. is a biopharmaceutical company specializing in precision oncology medicines. Since its founding in 2014, it has transitioned from research and development to a fully integrated commercial-stage company. Its lead product, KOMZIFTI (ziftomenib), is an FDA-approved oral menin inhibitor for treating adults with relapsed or refractory AML harboring NPM1 mutations. The company is advancing multiple clinical trials for ziftomenib in combination with standard AML therapies and is developing next-generation menin inhibitors targeting oncology and diabetes indications. Additionally, Kura is developing farnesyl transferase inhibitors for solid tumors. The company maintains a strong liquidity position as of Q3 2026 and continues to invest in pipeline expansion and commercialization efforts [S1][S2].
Kura Oncology, Inc. is a commercial-stage biopharmaceutical company focused on precision medicines for cancer, with a lead FDA-approved product, KOMZIFTI, for relapsed or refractory AML with NPM1 mutation. The company has a diversified pipeline including next-generation menin inhibitors for oncology and diabetes, and farnesyl transferase inhibitors for solid tumors. As of September 30, 2026, Kura Oncology reported $57.9 million in cash and cash equivalents, a current ratio of 3.6, and a net loss of $70.2 million for the quarter. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Recent news highlights include Q3 2026 earnings, commercial launch progress, and diabetes venture developments [S2][N1][N2][N7][N8].
Kura Oncology's lead product KOMZIFTI has achieved FDA approval with a differentiated profile in efficacy, safety, and dosing convenience, enabling commercial launch and market access in the U.S. The company is advancing multiple Phase 3 and Phase 1/2 clinical trials evaluating ziftomenib in combination with standard AML therapies, expanding its label and patient population. The development of next-generation menin inhibitors for diabetes and cardiometabolic diseases, supported by external investment, represents diversification beyond oncology. Additionally, ongoing development of farnesyl transferase inhibitors in solid tumors and head and neck cancers may broaden the pipeline. The company's liquidity position supports continued clinical and commercial activities. Recent milestone payments and initial sales of KOMZIFTI demonstrate early commercial traction [S1][S2][N1][N2][N7][N8].
Kura Oncology faces risks typical of biopharmaceutical companies including clinical trial uncertainties, regulatory challenges, and competitive pressures. The lead product KOMZIFTI carries a Black Box warning for differentiation syndrome, which may impact physician adoption and patient safety management. The company reported a net loss and negative EPS in the latest quarter, reflecting ongoing investment and commercialization costs. Market access and reimbursement dynamics could evolve, potentially affecting sales. Development of next-generation menin inhibitors and farnesyl transferase inhibitors is at early stages with inherent scientific and regulatory risks. Dependence on collaboration agreements, such as with Kyowa Kirin, introduces execution risks. Liquidity, while currently adequate, requires management to sustain operations through clinical development and commercialization phases [S1][S2].
Kura Oncology's moat is anchored in its FDA-approved KOMZIFTI, the first and only once-daily oral menin inhibitor for relapsed or refractory AML with NPM1 mutation, supported by robust clinical data and favorable safety profile. The product benefits from regulatory designations including Breakthrough Therapy and Orphan Drug status, and inclusion in NCCN Guidelines. The company's co-promotion agreement with Kyowa Kirin for U.S. commercialization and established market access with payors further strengthen its competitive position. Its diversified pipeline of next-generation menin inhibitors and farnesyl transferase inhibitors targeting oncology and diabetes indications adds potential for future differentiation. Intellectual property protection through multiple patents extending to 2044 supports exclusivity. These factors collectively contribute to a differentiated product offering and commercial infrastructure that create barriers to entry for competitors [S1].
• Clinical and Regulatory Risk: Clinical trials for KOMZIFTI combinations and pipeline candidates may not demonstrate sufficient safety or efficacy to support regulatory approvals or label expansions.
• Safety Profile Risk: KOMZIFTI carries a Black Box warning for differentiation syndrome, which may affect patient management and market acceptance.
• Commercial Execution Risk: Dependence on collaboration with Kyowa Kirin for commercialization outside the U.S. and profit-sharing arrangements in the U.S. may impact revenue and operational control.
• Financial Risk: The company reported net losses and negative earnings per share, requiring continued capital to fund operations and development programs.
• Market Access and Reimbursement Risk: Changes in payor coverage policies or reimbursement levels could affect KOMZIFTI sales and market penetration.
Business trends: Expansion of KOMZIFTI commercialization and clinical development of combination therapies in AML; diversification into diabetes and solid tumor indications.
Execution milestones: Progress in Phase 3 KOMET-017 trials, advancement of next-generation menin inhibitors including KO-7246, and ongoing farnesyl transferase inhibitor studies.
Key risks: Clinical and regulatory uncertainties, safety management of KOMZIFTI, financial sustainability amid losses, and reliance on collaboration agreements.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Kura Oncology, Inc. is a biopharmaceutical company focused on precision medicines for cancer treatment, evolving from R&D to a fully integrated commercial-stage organization with a diversified pipeline of small molecule product candidates targeting cancer signaling pathways [S1].
- The company’s lead product is KOMZIFTI (ziftomenib), an FDA-approved menin inhibitor for adults with relapsed or refractory AML with a susceptible NPM1 mutation, approved November 13, 2025 [S1].
- KOMZIFTI is the first and only FDA-approved menin inhibitor for once-daily oral administration, with a differentiated profile in efficacy, safety, compatibility, and simplicity [S1].
- KOMZIFTI’s approval was based on the KOMET-001 Phase 1/2 trial showing a CR+CRh rate of 21.4%, median duration of response of five months, and manageable safety profile with mostly Grade 1 or 2 adverse events [S1].
- KOMZIFTI carries a Black Box warning for differentiation syndrome (DS) but not for QTc prolongation, unlike other menin inhibitors [S1].
- The company initiated U.S. commercial sales of KOMZIFTI on November 21, 2025, sharing profits and losses equally with Kyowa Kirin under a co-promotion agreement; Kyowa Kirin handles commercialization outside the U.S. [S1].
- KOMZIFTI was added to NCCN Guidelines as a Category 2A recommended treatment for relapsed or refractory NPM1-mutated AML [S1].
- Market access for KOMZIFTI in the U.S. includes coverage by at least 80% of private payors aligned with the label, with some requiring step therapy before other menin inhibitors [S1].
- Kura Oncology is advancing multiple clinical trials for ziftomenib combinations in AML, including Phase 3 KOMET-017 trials for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged AML, testing combinations with intensive and non-intensive chemotherapy regimens [S1].
- Phase 1b KOMET-007 trial data showed high response rates and tolerability for ziftomenib combined with venetoclax and azacitidine in newly diagnosed and relapsed/refractory AML patients [S1].
- The company is evaluating ziftomenib in combination with other agents such as gilteritinib and quizartinib in specific AML subpopulations [S1].
- Kura Oncology is developing next-generation menin inhibitors for diabetes and cardiometabolic diseases, including KO-7246, with external investment and collaborations [S1].
- The company is also developing farnesyl transferase inhibitors (FTIs) such as darlifarnib and tipifarnib, with ongoing Phase 1 trials in solid tumors and head and neck squamous cell carcinoma (HNSCC) [S1].
- As of September 30, 2026, Kura Oncology reported cash and cash equivalents of $57.9 million, current assets of $534.7 million, current liabilities of $148.7 million, a current ratio of 3.6, and a cash ratio of 1.51, indicating liquidity [S2].
- The company reported a net loss of $70.2 million and basic and diluted EPS of -$0.78 for the quarter ended September 30, 2026 [S2].
- Recent news includes Q3 2026 earnings call transcript and report of Q3 loss with revenue exceeding expectations, launch of a $50M-backed diabetes venture for an oral menin inhibitor, and clinical development updates on diabetes candidate KO-7246 [N1][N2][N7][N8].
- Kura Oncology named Jennifer Fulk as CFO in September 2026 [N1].
- The company reported initial KOMZIFTI sales of $2.1 million and secured $195 million in milestone payments as of early 2026 [N1].
Generated 2026-11-11
- S1 | 2026-03-05 | 10-K
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-11-11 | www.nasdaq.com | Kura Oncology (KURA) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/kura-oncology-kura-q3-2026-earnings-call-transcript
- N2 | 2026-11-10 | www.nasdaq.com | Kura Oncology (KURA) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/kura-oncology-kura-reports-q3-loss-beats-revenue-estimates
- N3 | 2026-11-09 | www.nasdaq.com | Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/septerna-inc-sepn-reports-q3-loss-lags-revenue-estimates
- N4 | 2026-11-05 | www.nasdaq.com | Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-reports-q3-loss-beats-revenue-estimates
- N5 | 2026-11-04 | www.nasdaq.com | Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/cytek-biosciences-inc-ctkb-reports-q3-loss-tops-revenue-estimates
- N6 | 2026-10-27 | www.nasdaq.com | Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know | https://www.nasdaq.com/articles/will-kura-oncology-kura-report-negative-q3-earnings-what-you-should-know
- N7 | 2026-10-14 | www.nasdaq.com | Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor | https://www.nasdaq.com/articles/kura-oncology-launches-50m-backed-diabetes-venture-oral-menin-inhibitor
- N8 | 2026-10-13 | www.nasdaq.com | Caspian Therapeutics, Kura Oncology Outline Development Path For Diabetes Candidate KO-7246 | https://www.nasdaq.com/articles/caspian-therapeutics-kura-oncology-outline-development-path-diabetes-candidate-ko-7246
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


